PROCEPT BioRobotics (NASDAQ:PRCT) Reaches New 52-Week Low on Analyst Downgrade

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) shares reached a new 52-week low during mid-day trading on Wednesday after TD Cowen lowered their price target on the stock from $85.00 to $50.00. TD Cowen currently has a buy rating on the stock. PROCEPT BioRobotics traded as low as $31.72 and last traded at $32.5210, with a volume of 1295291 shares trading hands. The stock had previously closed at $35.02.

A number of other equities research analysts also recently weighed in on PRCT. Wall Street Zen raised PROCEPT BioRobotics from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Wells Fargo & Company lowered their price objective on PROCEPT BioRobotics from $58.00 to $51.00 and set an “overweight” rating on the stock in a research report on Wednesday. Piper Sandler restated an “overweight” rating and issued a $50.00 target price (down from $55.00) on shares of PROCEPT BioRobotics in a research note on Wednesday. Oppenheimer upgraded shares of PROCEPT BioRobotics from a “market perform” rating to an “outperform” rating and set a $60.00 price target on the stock in a research note on Tuesday, September 2nd. Finally, Leerink Partners reissued an “outperform” rating and issued a $55.00 target price on shares of PROCEPT BioRobotics in a research note on Wednesday. Nine analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, PROCEPT BioRobotics presently has a consensus rating of “Moderate Buy” and an average target price of $63.30.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of PRCT. Eagle Health Investments LP boosted its holdings in shares of PROCEPT BioRobotics by 3.1% in the 3rd quarter. Eagle Health Investments LP now owns 308,434 shares of the company’s stock worth $11,008,000 after acquiring an additional 9,345 shares in the last quarter. GSA Capital Partners LLP raised its position in PROCEPT BioRobotics by 400.2% in the 3rd quarter. GSA Capital Partners LLP now owns 33,310 shares of the company’s stock valued at $1,189,000 after purchasing an additional 26,651 shares during the last quarter. M&G PLC boosted its stake in PROCEPT BioRobotics by 3.3% in the third quarter. M&G PLC now owns 148,331 shares of the company’s stock worth $5,340,000 after purchasing an additional 4,772 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of PROCEPT BioRobotics by 93.4% during the third quarter. PNC Financial Services Group Inc. now owns 9,128 shares of the company’s stock worth $326,000 after purchasing an additional 4,408 shares during the last quarter. Finally, Alps Advisors Inc. grew its holdings in shares of PROCEPT BioRobotics by 64.8% during the third quarter. Alps Advisors Inc. now owns 22,523 shares of the company’s stock worth $804,000 after purchasing an additional 8,854 shares during the last quarter. Institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics Stock Performance

The stock has a 50 day moving average price of $36.02 and a two-hundred day moving average price of $47.66. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.44 and a quick ratio of 7.86. The company has a market capitalization of $1.78 billion, a price-to-earnings ratio of -20.86 and a beta of 0.98.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.03. The firm had revenue of $83.33 million for the quarter, compared to analyst estimates of $80.78 million. PROCEPT BioRobotics had a negative net margin of 28.20% and a negative return on equity of 21.72%. The company’s revenue was up 42.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.40) EPS. PROCEPT BioRobotics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. On average, analysts predict that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current fiscal year.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).